



Citation for published version:

Gracia-Lor, E, Rousis, NI, Zuccato, E, Bade, R, Baz Lomba, JA, Castrignanò, E, Causanilles, A, Hernández, F, Kasprzyk-Hordern, B, Kinyua, J, McCall, AK, van Nuijs, ALN, Plósz, BG, Ramin, P, Ryu, Y, Santos, MA, Thomas, K, de Voogt, P, Yang, Z & Castiglioni, S 2017, 'Estimation of caffeine intake from analysis of caffeine metabolites in wastewater', *Science of the Total Environment*, vol. 609, pp. 1582-1588.
<https://doi.org/10.1016/j.scitotenv.2017.07.258>

DOI:

[10.1016/j.scitotenv.2017.07.258](https://doi.org/10.1016/j.scitotenv.2017.07.258)

Publication date:

2017

Document Version

Peer reviewed version

[Link to publication](#)

Publisher Rights

CC BY-NC-ND

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1
2 **ESTIMATION OF CAFFEINE INTAKE FROM ANALYSIS OF CAFFEINE**
3 **METABOLITES IN WASTEWATER**
4

5 Emma Gracia-Lor^{a,b*}, Nikolaos I. Rousis^a, Ettore Zuccato^a, Richard Bade^{b,c}, Jose Antonio
6 Baz-Lomba^{d,e}, Erika Castrignanò^f, Ana Causanilles^g, Félix Hernández^b, Barbara Kasprzyk-
7 Hordern^f, Juliet Kinyua^h, Ann-Kathrin McCallⁱ, Alexander L.N. van Nuijs^h, Benedek G.
8 Plósz^{j,k}, Pedram Ramin^{i,l}, Yeonsuk Ryu^{d,e}, Miguel M. Santos^{m,n}, Kevin Thomas^{d,o}, Pim de
9 Voogt^{g,p}, Zhugen Yang^{f,q} and Sara Castiglioni^{a*}

10
11 ^aIRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Department of Environmental
12 Health Sciences, Via La Masa 19, 20156, Milan, Italy

13 ^bResearch Institute for Pesticides and Water, University Jaume I, Avda. Sos Baynat s/n, E-
14 12071, Castellon, Spain

15 ^cSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South
16 Australia 5000, Australia

17 ^dNorwegian Institute for Water Research (NIVA), Gaustadalléen 21, 0349 Oslo, Norway

18 ^eFaculty of Medicine, University of Oslo, PO box 1078 Blindern, 0316, Oslo, Norway

19 ^fUniversity of Bath, Department of Chemistry, Faculty of Science, Bath BA2 7AY, United
20 Kingdom

21 ^gKWR Watercycle Research Institute, Chemical Water Quality and Health, P.O. Box 1072,
22 3430 BB, Nieuwegein, The Netherlands

23 ^hToxicological Center, Department of Pharmaceutical Sciences, Campus Drie Eiken,
24 University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium

25 ⁱEawag, Swiss Federal Institute of Aquatic Science and Technology, CH-8600, Dübendorf,
26 Switzerland

27 ^jDepartment of Environmental Engineering, Technical University of Denmark,
28 Bygningstorvet, Building 115, DK-2800 Kgs. Lyngby, Denmark

29 ^kDepartment of Chemical Engineering, University of Bath, Claverton Down, Bath BA2 7AY,
30 UK

31 ^lDepartment of Chemical and Biochemical Engineering, Technical University of Denmark,
32 Søtofts Plads, Building 229, DK-2800 Kgs. Lyngby, Denmark

33 ^mCIMAR/CIIMAR-Interdisciplinary Centre of Marine and Environmental Research,
34 University of Porto, Avenida General Norton de Matos, S/N, 4450-208 Matosinhos, Portugal

35 ⁿFCUP – Department of Biology, Faculty of Sciences, University of Porto, Rua do Campo
36 Alegre, 4169-007 Porto, Portugal

37 ^oQueensland Alliance for Environmental Health Sciences (QAEHS), University of
38 Queensland, 39 Kessels Road Coopers Plains, Queensland 4108 Australia

39 ^pInstitute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, P.O. Box
40 94248, 1090 GE, Amsterdam, The Netherlands

41 ^qDivision of Biomedical Engineering, School of Engineering, University of Glasgow,
42 Glasgow G12 8LT United Kingdom

43

44 ***Corresponding author:**

45 E-mail addresses: lor@uji.es (E. Gracia-Lor), sara.castiglioni@marionegri.it (S. Castiglioni)

46

47 **ABSTRACT**

48 Caffeine metabolites in wastewater were investigated as potential biomarkers for
49 assessing caffeine intake in a population. The main human urinary metabolites of caffeine
50 were measured in the urban wastewater of ten European cities and the metabolic profiles in
51 wastewater were compared with the human urinary excretion profile. A good match was
52 found for 1,7-dimethyluric acid, an exclusive caffeine metabolite, suggesting that might be a
53 suitable biomarker in wastewater for assessing population-level caffeine consumption. A
54 correction factor was developed considering the percentage of excretion of this metabolite in
55 humans, according to published pharmacokinetic studies. Daily caffeine intake estimated
56 from wastewater analysis was compared with the average daily intake calculated from the
57 average amount of coffee consumed by country per capita. Good agreement was found in
58 some cities but further information is needed to standardize this approach. Wastewater
59 analysis proved useful to providing additional local information on caffeine use.

60

61 **Key words:** Caffeine; 1,7-dimethyluric acid; back-calculation; correction factor; wastewater-
62 based epidemiology; urinary biomarkers

63

64

65 1. INTRODUCTION

66 History suggests that caffeine has been used, in one form or another, since ancient
67 times. In 2737 BC a Chinese Emperor used the leaves from a nearby bush to prepare a tea
68 (Arab and Blumberg, 2008; Heckman et al., 2010). An old legend dates the use of coffee to
69 the 9th century in the southern tip of the Arabian Peninsula when a shepherd noted euphoria
70 and stimulating effects on his goats caused by eating wild coffee berries. He then decided to
71 try them himself. Coffee later crossed to Africa and in the 1600s reached Europe becoming,
72 over the centuries, the most commonly consumed beverage worldwide after water (Butt and
73 Tauseef, 2011).

74 Caffeine is a naturally occurring alkaloid found in beans, leaves and fruits of more
75 than 60 plant species. The world's main sources are coffee beans (*Coffea arabica* and *Coffea*
76 *robusta*) and tea leaves (*Camellia siniensis*). It is also naturally found in kola nuts (*Cola*
77 *acuminata*), cocoa beans (*Theobroma cacao*), yerba mate (*Ilex paraguariensis*) and guarana
78 berries (*Paullinia cupana*). Most caffeine is consumed with beverages such as coffee, tea and
79 soft drinks (including “energy drinks”), while products containing cocoa or chocolate, and
80 medications such as some analgesic formulations and dietary supplements contribute small
81 amounts to the diet (Heckman et al., 2010). Total daily intakes vary throughout the world
82 although coffee usually contributes significantly more than other drinks to overall caffeine
83 consumption (coffee 71%, soft drinks 16% and tea 12%), particularly among adults
84 (Heckman et al., 2010; Mitchell et al., 2014). Carbonated Soft drinks are the main source of
85 caffeine for children (Mitchell et al., 2014).

86 Chocolate contains on average around 1.3% of theobromine, 0.75% of caffeine and
87 theophylline in small amounts; cola nut between 2 and 3.5% of caffeine, theobromine
88 (between 1 and 3.5%) and small amounts of theophylline, and tea leaves around 3% of

89 caffeine (theophylline and theobromine in small amounts). This results in around 40-80 mg of
90 caffeine per cup of tea (150 mL) while caffeine content in cocoa commercial products ranges
91 from 2 to 7 mg (Barone and Roberts, 1996) and 5-20 mg/100 g in chocolate candy products.
92 In soft drinks, variable levels of caffeine have been reported depending on the brand but the
93 typical content is around 40 mg/360 mL (Chou and Bell, 2007). All these products contain
94 relatively little caffeine compared to the average content of a coffee cup (60-150 mg/150 mL).

95 Caffeine is extensively metabolized by the human liver to form three major
96 metabolites by demethylation: 3,7-dimethylxanthine (known as theobromine), 1,7-
97 dimethylxanthine (paraxanthine) and 1,3-dimethylxanthine (theophylline). These are then
98 broken down further in the liver by additional demethylation and oxidation and are excreted
99 mostly in the urine (Heckman et al., 2010).

100 While there is no specific recommendation for human caffeine intake, it is considered
101 that average consumption of approximately 300 mg/day is not associated with adverse health
102 effects (Fitt et al., 2013; Higdon and Frei, 2006). However, data about caffeine intake in the
103 population are scarce. Caffeine consumption is usually assessed by dietary surveys, but
104 getting accurate information in this way presents many limitations. For instance, subjects may
105 under-report their caffeine intake when food diaries are completed or information is missing
106 about the strength, brand or amount of caffeine product they have consumed, which may
107 greatly affect the intake. Another limitation is that in caffeine dietary surveys the subjects are
108 usually asked about the consumption of certain beverages (mainly coffee and tea) but other
109 products containing caffeine are not considered: for example, analgesics can contain as much
110 as 200 mg caffeine per tablet (Derbyshire and Abdula, 2008). Another limitation for
111 estimating the total caffeine intake is that the caffeine content of various drinks, food and
112 dietary supplements is only known in some countries such as the USA (Fitt et al., 2013).

113 A complementary method would be to estimate consumption in the general population
114 by using the levels of caffeine and its metabolites measured in urban wastewater as
115 biomarkers of intake. This approach, called *wastewater-based epidemiology* (WBE), has been
116 mainly applied in the last decade for estimating illicit drug consumption (Baker et al., 2014;
117 Ort et al., 2014; Thomas et al., 2012; Zuccato et al., 2008) and more recently has also been
118 proposed for the quantitative measurement of lifestyle habits such as tobacco and alcohol use,
119 exposure to environmental and food contaminants or factors related to health and illness in a
120 community (Lopes et al., 2014; Reid et al., 2011; Rodríguez-Álvarez et al., 2015; Rousis et
121 al., 2017; Thomas and Reid, 2011; Yang et al., 2015). The main advantage of WBE is that it
122 provides objective, up-to-date information about the use of these substances in a population
123 and can therefore complement current epidemiological methods.

124 In this study, the presence of caffeine and some selected metabolites was assessed in
125 untreated wastewater in ten European cities. Levels in wastewater were compared with those
126 measured in urine and with the human excretion profiles of caffeine reported in the literature
127 in order to correlate the results from the different sources. 1,7-dimethyluric acid, an exclusive
128 caffeine metabolite, was selected for estimating collective caffeine consumption. The
129 reliability of this compound for caffeine back-calculation was evaluated by comparing the
130 amounts measured by wastewater analysis with the average amount of coffee consumed in
131 each country per capita.

132

133 **2. MATERIALS AND METHODS**

134 **2.1 Chemicals and reagents**

135 Caffeine (1,3,7-trimethylxanthine), paraxanthine and 1-methylxanthine were purchased
136 from Sigma Aldrich (St. Louis, MO, USA); 1-methyluric acid, 1,7-dimethyluric acid 7-
137 methylxanthine were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, California,

138 USA). Standard solutions at 1 mg/mL were prepared in methanol, except for 1-
139 methylxanthine, 7-methylxanthine, paraxanthine and 1,7-dimethyluric acid which were
140 prepared in methanol-water (50/50) at pH 8.5-10 (adjusted with 25% ammonia to enhance
141 solubility). A mix of all compounds at 10 ng/ μ L was prepared in methanol and then diluted to
142 1.0, 0.1 and 0.01 ng/ μ L. Isotopically labeled compounds were caffeine- $^{13}\text{C}_3$ purchased from
143 Sigma Aldrich and 1,7-dimethyluric acid- d_3 from Santa Cruz Biotechnology. Labeled internal
144 solutions were prepared separately. Internal standard mixtures with 1 ng/ μ L of caffeine- $^{13}\text{C}_3$
145 and 10 ng/ μ L of 1,7-dimethyluric acid- d_3 were used as surrogates.

146 All solvents were of reagent grade or higher. Methanol for pesticide analysis and
147 ammonium acetate were from Carlo Erba Reagents (Italy). Ammonium hydroxide solution
148 (25%) was acquired from Fluka (Buchs, Switzerland). LC-MS grade acetonitrile and
149 hydrochloric acid (37%) were supplied by Riedel de Haen (Seelze, Germany). Water was
150 purified using Milli-RO Plus 90 apparatus (Millipore, Molsheim, France). Solid-phase
151 cartridges (3 mL Oasis HLB, 60 mg) and HPLC XTerra C18 column (3.5 μm , 1 mm \times 100
152 mm) were obtained from Waters Corp., Milford, MA, USA.

153

154 **2.2 Wastewater samples**

155 24-hour composite influent wastewater samples were collected from ten wastewater
156 treatment plants (WWTP) in different European cities: Bristol (UK), Brussels (Belgium),
157 Castellón (Spain), Copenhagen (Denmark), Lugano (Switzerland), Milan (Italy), Oslo
158 (Norway), Porto (Portugal), Utrecht (Netherlands) and Zurich (Switzerland) (**Table S2**).
159 Samples were collected daily for seven consecutive days in March 2015 and April 2015
160 (Porto), frozen immediately after collection to prevent degradation of the compounds and sent
161 to Milan within 24 hours in cooler boxes with dry ice or ice packs to keep them frozen.

162 Samples were stored at -20°C until analysis. For each sample the flow rate of the sewage
163 stream (L/day) was recorded.

164

165 **2.3 Extraction and analysis**

166 Before solid phase extraction, samples were thawed in a warm bath, then filtered to
167 remove suspended particulate matter through 1.6 µm GF/A glass microfiber filters and 0.45
168 µm mixed cellulose membrane filters from Whatman (Kent, UK). Then 3 mL of filtered
169 wastewater were spiked with labeled internal standards (20 ng of caffeine-¹³C₃ and 200 ng
170 1,7-dimethyluric acid-d₃) and, if necessary, the pH was adjusted to 6.0-7.5 with 12% ~~HCl~~
171 (v/v). Samples were loaded on Oasis HLB cartridges (3 mL, 60 mg), previously conditioned
172 with 6 mL of MeOH and 3 mL of water. Cartridges were vacuum-dried for 10 minutes,
173 wrapped in aluminum foil and immediately stored at -20 °C. For analysis, cartridges were
174 eluted with 2 mL of methanol and the extract was evaporated to dryness under a nitrogen
175 stream. Dry residues were redissolved in 100 µL MeOH-ultrapure water (20:80, v/v),
176 centrifuged and transferred into glass vials for instrumental analysis. One µL of the final
177 extract was injected into the liquid chromatography coupled to tandem mass spectrometry
178 system (LC-MS/MS). The analyses were done by high-performance liquid chromatography
179 (1200 Series pumps system, Agilent Technologies, CA) coupled to a triple quadrupole mass
180 spectrometer (AB SCIEX QqQ 5500, Ontario, Canada). Samples were analysed using the
181 positive electrospray ionization mode. Experimental conditions and detailed analytical
182 conditions are described in **Table S3** and **S4** and in more detail in Senta et al., 2015.

183

184 **2.4. Daily mass loads and back-calculation of consumption**

185 The daily mass loads (g/day) of the selected analytes were calculated multiplying the
186 measured concentrations of caffeine and metabolites (ng/L) by the daily flow rate of
187 wastewater (L/day) at the entry of each WWTP.

188 Caffeine consumption was back-calculated using the approach proposed for illicit
189 drugs by Zuccato et al., 2008. Specific correction factors were developed taking into account
190 the percentage of urinary excretion of each metabolite and the molar mass ratio of the parent
191 compound to the metabolite. All the pharmacokinetic studies accessible in the literature which
192 reported data on the human urinary excretion of caffeine after oral administration (eight in all,
193 see **Supplemental Information**) were reviewed to develop a specific correction factor for
194 back-calculating caffeine intake by the population. The mean percentage of excretion of
195 caffeine and its metabolites was calculated by weighting the number of subjects in each study.
196 The total uncertainty related to the back-calculation procedure was evaluated as the standard
197 deviation (SD) of the mean percentage of excretion (**Table 1**). This method had been
198 previously proposed for refining the correction factors of the most used illicit drugs
199 (Castiglioni et al., 2013; Gracia-Lor et al., 2016).

200 **Table 1.** Metabolic profiles of caffeine and its main metabolites in human urine (from pharmacokinetic studies and spot urine analysis) and from
 201 the levels measured in wastewater.

Compound	Mean excretion (%) from pharmacokinetic studies (SD)	Geometric mean from spot urine analysis (95%CI) (2466 subjects)^a	Mean excretion (%) from wastewater analysis (SD) (70 samples)
caffeine (1,3,7-trimethylxanthine)	1.7 (1.0)	1.81 (1.57-2.08)	20.9 (6.0)
paraxanthine (1,7-dimethylxanthine)	4.6 (1.4)	7.47 (6.73-8.29)	22.1 (4.0)
1-methylxanthine	10.0 (3.4)	17.1 (15.4-19.0)	15.8 (3.5)
7-methylxanthine	3.1 (1.2)	31.4 (28.6-34.3)	24.9 (6.4)
1-methyluric acid	16.5 (6.2)	39.4 (35.8-43.4)	4.7 (1.1)
1,7-dimethyluric acid	6.7 (2.3)	12.2 (11.0-13.6)	11.6 (2.0)
theophylline (1,3-dimethylxanthine)	0.6 (0.4)	0.872 (0.796-0.955)	Not analyzed
theobromine (3,7-dimethylxanthine)	1.5 (1.3)	12.4 (11.4-13.5)	Not analyzed
1,3-dimethyluric acid	1.6 (0.7)	3.51 (3.17-3.89)	Not analyzed
3,7-dimethyluric acid	0.2 (0.4)	0.784 (0.714-0.861)	Not analyzed
3-methylxanthine	2.0 (1.1)	19.2 (17.5-21.0)	Not analyzed

202

203 ^aData taken from Rybak et al., 2014


204

205 3. RESULTS AND DISCUSSION

206 3.1 Caffeine biomarkers for back-calculation

207 Selecting a substance as a biomarker is not easy to achieve as it must have specific
208 characteristics (Gracia-Lor et al., 2016): i) be excreted in measurable quantities in wastewater;
209 ii) be released to sewers exclusively from human excretion; iii) be unique to human
210 metabolism to ensure that it comes only from human excretion and not from exogenous
211 sources; iv) have low adsorption for suspended particulate; v) be stable in wastewater during
212 in-sewer transport, and during storage and analysis.

213 Each substance for this investigation was tested as a suitable biomarker of caffeine
214 consumption as described above. Caffeine itself is not a good candidate because it comes not
215 only from coffee but also from other sources. Caffeine metabolites too may originate from
216 other naturally occurring alkaloids with similar structures, such as theobromine and
217 theophylline, which themselves are also caffeine metabolites (**Figure 1**). Theobromine is
218 present in cocoa beans (and subsequently in chocolate), tea leaves and cola beans.
219 Theophylline is present in tea leaves in small amounts but is also used medically, for instance
220 for asthma and other lung diseases (Senchina et al., 2014). Specifically, among five caffeine
221 metabolites studied, 1-methylxanthine and 1-methyluric acid are also metabolites of
222 theophylline, while 7-methylxanthine is the major metabolite of theobromine. Paraxanthine
223 and 1,7-dimethyluric acid however, are exclusively metabolites of caffeine (**Figure 1**). Thus,
224 they are potentially the most suitable biomarkers to back-calculate the amount of caffeine
225 consumed, i.e. the consumption of all products containing caffeine (coffee, chocolate, tea,
226 etc). As they come only from human excretion and not from exogenous sources, their
227 presence can play an important role in identifying fresh water or ground water contaminated
228 by sewage.




229
230

231 **Figure 1.** Metabolic pathway of caffeine in humans

232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251

3.2 Metabolic profiles in wastewater and in human urine

According to the human urinary excretion profile of caffeine, the mass loads of 1-methyluric acid should be the highest, followed by 1-methylxanthine, 1,7-dimethyluric acid, paraxanthine, 7-methylxanthine and finally, caffeine (**Table 1**). However, the quantitative profiles of caffeine and the metabolites calculated from wastewater analysis did not completely agree with the human excretion profile. The mass loads (mean of the ten cities) decreased as follows: 7-methylxanthine > paraxanthine > caffeine > 1-methylxanthine > 1,7-dimethyluric acid > 1-methyluric acid (**Figure 2**). Hence, there are large differences from the human excretion profile of caffeine. We therefore included supplementary data from spot urine analysis in our comparison (**Table 1**). These percentages (geometric mean, 95% CI) were obtained from Rybak et al., 2014, who recently measured caffeine and 14 metabolites in more than 2000 urine samples. We calculated also the percentages of excretion using the concentrations measured in wastewater in the ten European cities (**Table 1**). Each metabolite is reported as a percentage of the sum of the levels of metabolites plus caffeine measured in wastewater, following the procedure employed by Castiglioni et al., 2011 to calculate the metabolic profile of cocaine in wastewater and in human urine. The excretion profiles of caffeine and its metabolites were calculated using median values because of the high variability of the concentrations.



253

254 **Figure 2.** Normalized mass loads (g/day/1000 inhabitants) of caffeine and its metabolites in
 255 ten European cities in March 2015 and April 2015 (Porto). Means \pm standard deviation (SD)
 256 of seven-day samples (only the upper limit of the SD bar is shown).

257 Data from wastewater could be reasonably compared with the profiles in spot urine
258 samples, since they indicate respectively the profiles of excretion from an entire community
259 and from single individuals. Percentages were comparable for 1-methylxanthine and 7-
260 methylxanthine acid in wastewater and spot urine samples, but higher than in
261 pharmacokinetic studies (**Table 1**). This can be easily explained by the fact that they are also
262 metabolites of theophylline and theobromine respectively. The percentage of caffeine in
263 wastewater (21%) was much higher than expected from spot urine analysis and
264 pharmacokinetic studies (1.8% and 1.7%). There might therefore be other sources of caffeine
265 contributing to the total amount in wastewater (e.g., coffee grounds that are disposed down of
266 the sink drain, disposal of coffee that was not drunk or improper disposal of caffeine for
267 pharmacological use). In contrast, for 1-methyluric acid the percentage in wastewater was
268 lower than in urine and in pharmacokinetic studies. A possible explanation could be
269 degradation of this compound in wastewater such as in-sewer, during transport or during
270 storage. This should be verified by in-sewer experiments and additional modeling studies.

271 Some differences were observed for paraxanthine (22.1% of the total in wastewater,
272 4.6% in pharmacokinetic studies and 7.5% in spot urine samples); however for 1,7-
273 dimethyluric acid the results were comparable (approximately 12% of the measured
274 concentrations in wastewater and in spot urine samples, and 4.3-12.6% of the administered
275 dose in pharmacokinetic studies (see data in SI)). Taking to account of all these
276 considerations, 1,7-dimethyluric acid seemed to be the most suitable biomarker for the back-
277 calculation of caffeine. The mean percentage of excretion of this metabolite weighted by the
278 number of subjects in each study (6.7%) and the 1,7-dimethyluric acid/caffeine molecular
279 mass ratio were used to obtain the correction factor (CF), according to the following equation:

$$CF = \frac{Mw_{caffeine} / Mw_{1,7-dimethyluric\ acid}}{Mean\ excretion_{1,7-dimethyluric\ acid}} = \frac{194.08 / 196.06}{0.067} = 14.8$$

281 where M_w is the molecular weight and the mean excretion is the weighted mean of the
282 percentage of excretion of the target metabolite.

283

284 **3.3 Estimation of caffeine consumption**

285 Using the proposed correction factor, caffeine consumption (in mg/day/person) in
286 each city was calculated based on the wastewater measurements of 1,7-dimethyluric acid. The
287 mean daily consumption of caffeine per capita ranged from 263 mg/day/person in Zurich to
288 87 mg/day/person in Milan (**Table 2**). These data match the mean daily caffeine intake in
289 Europe of around 300 mg/day/person estimated by the European Food Safety Authority
290 (means range from 37 to 320 mg/day/person estimated from individual surveys for adults
291 between 18 and 64 years) (European Food Safety Authority (EFSA), 2015).

292 For a more accurate comparison, we compared our wastewater analysis data to the
293 amount of coffee consumed per country per capita (per person on average), which reflects the
294 imports of coffee by each country, according to the International Coffee Organization (ICO)
295 (International Coffee Organization (ICO), 2015). We converted the per capita consumption
296 (in kg/person) of coffee to the daily intake of caffeine per person considering that dry coffee
297 beans contain about 1.1% of caffeine in Arabica and about 2.2% in Robusta coffee. In 2015,
298 around 60% of the coffee exported was Arabica (“International Coffee Organization,” 2015),
299 but the proportion can change from country to country. For instance, according to Garattini,
300 1993, consumer countries can be classified in three levels: (a) where consumption of Arabica
301 accounts for more than 70% (Switzerland and Northern European countries, i.e. Norway and
302 Denmark); (b) where consumption of Arabica is around 50% (Italy, the Netherlands, Belgium
303 and the UK); (c) where consumption of Robusta predominates (Spain and Portugal) (**Table**
304 **2**). In addition, the amount of caffeine extracted varies with the preparation method, ranging
305 from 75% in boiled coffee to nearly 100% in filtered coffee. To estimate the amount of

306 caffeine in the coffee we took 1.1% for countries classified in group (a), 1.6% (i.e. mean
307 caffeine content in Arabica and in Robusta) for countries belonging to group (b) and 2.2% for
308 countries in group (c). In all cases, we assumed 95% extraction efficiency, as previously
309 proposed (Fredholm et al., 1999).

310 For four cities (Oslo, Copenhagen, Zurich and Brussels), the difference was 20% or
311 less. The amounts for Castellón, Utrecht, Milan, Lugano and Porto estimated from wastewater
312 analysis were lower than indicated by the coffee trade figures, and higher in Bristol. This
313 might be due to different factors: first of all, we compared data from whole country with data
314 in a specific city, while population habits might be different. This was the case for Zurich and
315 Lugano, two Swiss cities: a 20% difference was obtained for Zurich (410,000 inhabitants),
316 whilst it was around 50% for Lugano (100,000 inhabitants). Secondly, we compared annual
317 coffee trade figures with caffeine estimated through wastewater analysis in one week. Finally,
318 data obtained through back-calculation refer to the amount of caffeine consumed in all
319 products that contain relatively large amounts such as coffee, chocolate, soft drinks and
320 medications. Thus, larger amounts of caffeine estimated through the wastewater analysis in
321 Zurich, Copenhagen, and especially in Bristol, might be due to higher consumption of other
322 products in those countries. Switzerland is in fact the country with the highest per capita
323 consumption of chocolate, and the UK is also among the countries with the highest
324 consumption, according to different sources (Statista, 2015; Target Map, 2015)). Another
325 reason might be the fact that the caffeine content of coffee in the UK is higher than in other
326 countries (Barone and Roberts, 1996). Furthermore, tea containing around 3% of caffeine is
327 the most popular drink in the UK today, and contributes to caffeine consumption. In five
328 cities, the difference was of at least 50%.

329 **Table 2.** Caffeine consumption estimated from wastewater analysis and using coffee trade data for the countries investigated. The difference was
 330 calculated between the estimates from international statistics and from wastewater analysis.

Cities investigated (country)	Caffeine from wastewater analysis	Caffeine from international statistics*			Difference (%)
	mg caffeine/day/person (SD)	Kg coffee/year/person*	Type of coffee mostly consumed ^a	mg caffeine/day/person	
Bristol (UK)	190 (37)	3.3	50% Arabica-50% Robusta	137	-38
Brussels (Belgium)	162 (15)	4.3	50% Arabica-50% Robusta	179	16
Castellón (Spain)	122 (28)	4.5	Robusta	258	53
Copenhagen (Denmark)	229 (19)	6.9	Arabica	198	-16
Lugano (Switzerland)	97 (16)	7.6	Arabica	218	55
Milan (Italy)	86 (18)	5.6	50% Arabica-50% Robusta	233	63
Oslo (Norway)	211 (21)	8.7	Arabica	249	15
Porto (Portugal)	121 (27)	4.8	Robusta	275	56
Utrecht (The Netherlands)	107 (28)	5.3	50% Arabica-50% Robusta	221	51
Zurich (Switzerland)	263 (23)	7.6	Arabica	218	-20

331

332 *Source: International Coffee Organization (ICO), 2015 (<http://www.ico.org/coffee-trade-statistics-infographics.asp>)

333 ^a(Garattini, 1993)

334 The aim of the comparison between the amount of caffeine consumed, estimated from
335 the wastewater analysis, and coffee consumption figures from international trade was mainly
336 to check whether the proposed metabolite was a suitable biomarker of consumption. The
337 results indicate that 1,7-dimethyluric acid can be used for this purpose, although additional
338 studies are needed to validate this approach, including more extensive wastewater sampling
339 campaigns in different countries.

340 Additional information on the current proportions (percentages) of commercial
341 varieties of coffee consumed in each country is also needed for more accurate comparisons.
342 There are some differences between coffee consumption data, in terms of the amount
343 consumed in each country per capita, published by different sources (for instance, between the
344 ICO (International Coffee Organization (ICO), 2015) which is based on coffee imports and
345 exports and Euromonitor International (Caffeine Informer, 2016), which deals with local
346 business information). This is another factor that may influence the accuracy of a data
347 comparison.

348 Additionally, only eight studies could be found dealing with the human excretion of
349 caffeine, so more pharmacological studies are essential to improve the reliability of urinary
350 excretion profiles and the correction factors used to back-calculate caffeine consumption. At
351 present, these studies are scarce and most are quite old and based on a small number of
352 subjects (Gracia-Lor et al., 2016).

353

354 **4. CONCLUSIONS**

355 Profiles of caffeine metabolites in wastewater reasonably matched the profiles in spot
356 urine samples suggesting that the analysis in wastewater might reflect the collective
357 consumption of caffeine-containing products.

358 We selected 1,7-dimethyluric acid for caffeine back-calculation because it is an
359 exclusive human metabolite of caffeine and so it is only produced by consumption of products

360 containing caffeine (i.e. coffee, tea, chocolate, etc.). The percentage of its excretion from
361 pharmacokinetic studies is similar to the profiles found in urine and in wastewater (estimated
362 from 70 influent wastewater samples collected in ten European cities). The mean daily
363 consumption of caffeine per capita, estimated from wastewater analysis using the correction
364 factor proposed, matched the mean daily caffeine intake (from 37 to 320 mg/day/person
365 estimated from individual surveys for adults 18-64 years old). In four cities a good correlation
366 was seen between wastewater analysis and the amount of coffee consumed in the country per
367 capita. Several factors might explain discrepancies in the other six cities. For instance the
368 estimation of coffee consumption on the basis of the imports of coffee by each country is
369 influenced by many uncertainties, so it is hard to estimate the consumption of other
370 commodities contributing to caffeine intake. Furthermore, the correction factor may be
371 imprecise due to uncertainties in the metabolism studies in the literature. Thus, new studies
372 are needed about the metabolism and urinary excretion of caffeine in realistic intake amounts.
373 Stability tests of biomarkers in sewers are also needed.

374

375 **CONTRIBUTIONS**

376 Emma Gracia-Lor, Ettore Zuccato and Sara Castiglioni planned and designed the
377 study. The collection of the wastewater samples was organized by all authors. Emma Gracia-
378 Lor analyzed the samples and interpreted the results with the input of Nikolaos I. Rousis and
379 Sara Castiglioni. Emma Gracia-Lor drafted the manuscript, which was critically revised by all
380 co-authors. All authors are aware of the content, and accept responsibility, for the manuscript.

381

382 **ACKNOWLEDGMENTS**

383 Financial support from the SEWPROF Marie Curie ITN project ‘A new paradigm in
384 drug use and human health risk assessment: Sewage profiling at the community level’ [grant

385 agreement 317205] supported by the European Union's Seventh Framework Programme for
386 research, technological development and demonstration and from the COST Action ES1307
387 “SCORE – Sewage biomarker analysis for community health assessment” is gratefully
388 acknowledged. Emma Gracia-Lor extends her gratitude to Generalitat Valenciana, Conselleria
389 d’Educació, Investigació, Cultura i Esport for her postdoctoral contract (APOSTD/2015,
390 Programa VALi+d). Alexander van Nuijs acknowledges FWO Flanders for financial support.
391 We are grateful to Christoph Ort for his comments and suggestions and to the personnel from
392 all WWTPs for their support in wastewater sampling, particularly Francesco Poretti and
393 Armando Foletti from Consorzio Depurazione Acque Lugano e Dintorni (CDALED) in
394 Lugano for their kind support.

395

396

397

398 **REFERENCES**

- 399 Arab, L., Blumberg, B., 2008. Introduction to the proceedings of the Third International
400 Scientific Symposium on Tea and Human Health. *J. Nutr.* 138, 1826–1528.
401 doi:10.3945/ajcn.113.060186.Am
- 402 Baker, D.R., Barron, L., Kasprzyk-Hordern, B., 2014. Illicit and pharmaceutical drug
403 consumption estimated via wastewater analysis. Part A: Chemical analysis and drug use
404 estimates. *Sci. Total Environ.* 487, 629–641. doi:10.1016/j.scitotenv.2013.11.107
- 405 Barone, J.J., Roberts, H.R., 1996. Caffeine consumption. *Food Chem. Toxicol.* 34, 119–129.
- 406 Butt, M.S., Tauseef, S.M., 2011. Coffee and its Consumption: Benefits and Risks. *Crit. Rev.*
407 *Food Sci. Nutr.* 51, 363–373. doi:10.1080/10408390903586412
- 408 Caffeine Informer, 2016. Caffeine (coffee) consumption by country.
409 <http://www.caffeineinformer.com/caffeine-what-the-world-drinks>. (accessed 3.1.16).
- 410 Castiglioni, S., Bagnati, R., Melis, M., Panawennage, D., Chiarelli, P., Fanelli, R., Zuccato,
411 E., 2011. Identification of cocaine and its metabolites in urban wastewater and
412 comparison with the human excretion profile in urine. *Water Res.* 45, 5141–5150.
413 doi:10.1016/j.watres.2011.07.017
- 414 Castiglioni, S., Bijlsma, L., Covaci, A., Emke, E., Hernández, F., Reid, M., Ort, C., Thomas,
415 K. V., Van Nuijs, A.L.N., De Voogt, P., Zuccato, E., 2013. Evaluation of uncertainties
416 associated with the determination of community drug use through the measurement of
417 sewage drug biomarkers. *Environ. Sci. Technol.* 47, 1452–1460. doi:10.1021/es302722f
- 418 Chou, K.H., Bell, L.N., 2007. Caffeine content of prepackaged national-brand and private-
419 label carbonated beverages. *J. Food Sci.* 72. doi:10.1111/j.1750-3841.2007.00414.x
- 420 Derbyshire, E., Abdula, S., 2008. Habitual caffeine intake in women of childbearing age.
421 *J.Hum.Nutr.Diet.* 21, 159–164.
- 422 European Food Safety Authority (EFSA), 2015. Scientific Opinion in the safety of caffeine.

423 Eur. Food Saf. J. doi:10.2903/j.efsa.20YY.NNNN

424 Fitt, E., Pell, D., Cole, D., 2013. Assessing caffeine intake in the United Kingdom diet. Food
425 Chem. 140, 421–426. doi:10.1016/j.foodchem.2012.07.092

426 Fredholm, B.B., Bättig, K., Holmén, J., Nehlig, A., Zvartau, E.E., 1999. Actions of caffeine in
427 the brain with special reference to factors that contribute to its widespread use.
428 Pharmacol. Rev. 51, 83–133. doi:0031-6997/99/5101-0083\$03.00/0

429 Garattini, S., 1993. Caffeine, Coffee, and Health. Raven Press, New York.

430 Gracia-Lor, E., Zuccato, E., Castiglioni, S., 2016. Refining correction factors for back-
431 calculation of illicit drug use. Sci. Total Environ. 573, 1648–1659.
432 doi:10.1016/j.scitotenv.2016.09.179

433 Heckman, M.A., Weil, J., de Mejia, E.G., 2010. Caffeine (1, 3, 7-trimethylxanthine) in foods:
434 A comprehensive review on consumption, functionality, safety, and regulatory matters.
435 J. Food Sci. 75, 77–87. doi:10.1111/j.1750-3841.2010.01561.x

436 Higdon, J. V., Frei, B., 2006. Coffee and Health: A Review of Recent Human Research. Crit.
437 Rev. Food Sci. Nutr. 46, 101–124. doi:10.1080/10408390500400009

438 International Coffee Organization (ICO), 2015. Global coffee trade.
439 <http://www.ico.org/coffee-trade-statistics-infographics.asp> (accessed 1.15.16).

440 International Coffee Organization, 2015. <http://www.ico.org/>

441 Lopes, A., Silva, N., Bronze, M.R., Ferreira, J., Morais, J., 2014. Analysis of cocaine and
442 nicotine metabolites in wastewater by liquid chromatography-tandem mass spectrometry.
443 Cross abuse index patterns on a major community. Sci. Total Environ. 487, 673–680.
444 doi:10.1016/j.scitotenv.2013.10.042

445 Mitchell, D.C., Knight, C. A., Hockenberry, J., Teplansky, R., Hartman, T.J., 2014. Beverage
446 caffeine intakes in the U.S. Food Chem. Toxicol. 63, 136–142.
447 doi:10.1016/j.fct.2013.10.042

448 Ort, C., van Nuijs, A.L.N., Berset, J.D., Bijlsma, L., Castiglioni, S., Covaci, A., de Voogt, P.,
449 Emke, E., Fatta-Kassinos, D., Griffiths, P., Hernández, F., González-Mariño, I., Grabic,
450 R., Kasprzyk-Hordern, B., Mastroianni, N., Meierjohann, A., Nefau, T., Östman, M.,
451 Pico, Y., Racamonde, I., Reid, M., Slobodnik, J., Terzic, S., Thomaidis, N., Thomas, K.
452 V., 2014. Spatial differences and temporal changes in illicit drug use in Europe
453 quantified by wastewater analysis. *Addiction* 109, 1338–1352. doi:10.1111/add.12570

454 Reid, M.J., Langford, K.H., Mørland, J., Thomas, K. V., 2011. Analysis and interpretation of
455 specific ethanol metabolites, ethyl sulfate, and ethyl glucuronide in sewage effluent for
456 the quantitative measurement of regional alcohol consumption. *Alcohol. Clin. Exp. Res.*
457 35, 1593–1599. doi:10.1111/j.1530-0277.2011.01505.x

458 Rodríguez-Álvarez, T., Racamonde, I., González-Mariño, I., Borsotti, A., Rodil, R.,
459 Rodríguez, I., Zuccato, E., Quintana, J.B., Castiglioni, S., 2015. Alcohol and cocaine co-
460 consumption in two European cities assessed by wastewater analysis. *Sci. Total Environ.*
461 536, 91–8. doi:10.1016/j.scitotenv.2015.07.016

462 Rousis, N.I., Zuccato, E., Castiglioni, S., 2017. Wastewater-based epidemiology to assess
463 human exposure to pyrethroid pesticides. *Environ. Int.* 99, 213–220.
464 doi:10.1016/j.envint.2016.11.020

465 Rybak, M.E., Pao, C.I., Pfeiffer, C.M., 2014. Determination of urine caffeine and its
466 metabolites by use of high-performance liquid chromatography-tandem mass
467 spectrometry: Estimating dietary caffeine exposure and metabolic phenotyping in
468 population studies. *Anal. Bioanal. Chem.* 406, 771–784. doi:10.1007/s00216-013-7506-9

469 Senchina, D.S., Hallam, J.E., Kohut, M.L., Nguyen, N.A., Perera, M.A.D.N., 2014. Alkaloids
470 and athlete immune function: caffeine, theophylline, gingerol, ephedrine, and their
471 congeners. *Exerc. Immunol. Rev.* 20, 68–93.

472 Statista, 2015. Per capita consumption of chocolate confectionery worldwide in 2015, by key

473 markets (in kilograms). <https://www.statista.com/statistics/263779/per-capita->
474 [consumption-of-chocolate-in-selected-countries-in-2007/](https://www.statista.com/statistics/263779/per-capita-consumption-of-chocolate-in-selected-countries-in-2007/) (accessed 2.2.17).

475 Target Map, 2015. The Chocolate League Tables 2014: Top 20 consuming nations.
476 <http://www.targetmap.com/viewer.aspx?reportId=38038> (accessed 2.2.17).

477 Thomas, K. V., Bijlsma, L., Castiglioni, S., Covaci, A., Emke, E., Grabic, R., Hernández, F.,
478 Karolak, S., Kasprzyk-Hordern, B., Lindberg, R.H., Lopez de Alda, M., Meierjohann,
479 A., Ort, C., Pico, Y., Quintana, J.B., Reid, M., Rieckermann, J., Terzic, S., van Nuijs,
480 A.L.N., de Voogt, P., 2012. Comparing illicit drug use in 19 European cities through
481 sewage analysis. *Sci. Total Environ.* 432, 432–439. doi:10.1016/j.scitotenv.2012.06.069

482 Thomas, K. V., Reid, M.J., 2011. What Else Can the Analysis of Sewage for Urinary
483 Biomarkers Reveal About Communities? *Environ. Sci. Technol.* 45, 7611–7612.
484 doi:10.1021/es202522d

485 Yang, Z., D’Uriac, M.A., Goggins, S., Kasprzyk-Hordern, B., Thomas, K. V., Frost, C.G.,
486 Estrela, P., 2015. A novel DNA biosensor using a ferrocenyl intercalator applied to the
487 potential detection of human population biomarkers in wastewater. *Environ. Sci.*
488 *Technol.* 49, 5609–5617. doi:10.1021/acs.est.5b00637

489 Zuccato, E., Chiabrando, C., Castiglioni, S., Bagnati, R., Fanelli, R., 2008. Estimating
490 community drug abuse by wastewater analysis. *Environ. Health Perspect.* 116, 1027–
491 1032. doi:10.1289/ehp.11022

492